AI Drug Discovery Firm Derui Zhiyao Secures $52 Million in Series B Funding
Derui Zhiyao, a technology company specializing in AI-driven new drug research and development, has announced the completion of its Series B financing round, totaling $52 million. The funding was secured in stages with investments from multiple institutions and industrial funds. Kai Cheng Capital served as the exclusive financial advisor for this round. The capital raised will be primarily allocated to the technological advancement of the company's proprietary full-chain AI drug manufacturing engine, known as the Molecule Arts Platform (MAP). This includes enhancing its Multi-Agent collaborative system and its Clinical Data-in-the-Loop capabilities. Additionally, the funds will support the Phase III clinical development and commercialization of Derui Zhiyao's self-developed oral GLP-1RA small molecule drug, MDR-001. The company also plans to accelerate the expansion of its pipeline of differentiated innovative drugs.
This funding round signifies continued investor confidence in the potential of artificial intelligence to revolutionize pharmaceutical research and development. By securing substantial capital, Derui Zhiyao is positioned to accelerate its technological roadmap, particularly in refining its AI engine for drug discovery and development. The focus on both platform enhancement and advancing a specific drug candidate, MDR-001, suggests a dual strategy of building long-term technological capabilities while pursuing near-term market opportunities. The success of this strategy will depend on the efficacy of its AI in generating novel and effective therapies, navigating complex clinical trial processes, and ultimately achieving commercial viability in a highly competitive and regulated industry. The integration of multi-agent systems and clinical data loops indicates a sophisticated approach to AI-driven drug development, aiming to create more efficient and data-informed decision-making throughout the R&D lifecycle.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.